Can a patient on gabapentin 200 mg three times daily be switched to pregabalin (Lyrica) by stopping gabapentin abruptly and starting pregabalin immediately?

Switching from Gabapentin 200 mg TID to Pregabalin

Do not abruptly discontinue gabapentin 200 mg three times daily when switching to pregabalin; instead, initiate pregabalin at 75 mg twice daily while continuing the morning dose of gabapentin for at least the first few days, then gradually taper gabapentin over several days to weeks to avoid withdrawal symptoms. 1

Recommended Transition Protocol

The American Academy of Neurology provides clear guidance for this switch:

• Start pregabalin at 75 mg twice daily (150 mg/day total) while maintaining your patient's current gabapentin regimen initially 1
• Continue at least the morning dose of gabapentin for the first few days of overlap 1
• Taper gabapentin gradually over several days to weeks rather than stopping abruptly 1
• The minimum tapering period for any gabapentinoid is one week, though extending to 2 weeks per step is advisable if withdrawal symptoms emerge 1

Why Gradual Transition Matters

Both medications must be tapered to prevent withdrawal symptoms—this is a critical safety consideration:

• Never abruptly discontinue either gabapentin or pregabalin; both require gradual tapering over a minimum of 1 week 1
• The Mayo Clinic emphasizes that adequate tapering prevents withdrawal symptoms that can occur with sudden cessation 1
• Your patient's current dose of gabapentin 200 mg TID (600 mg/day total) is relatively low, but the tapering principle still applies 2

Pregabalin Dosing After Transition

Once gabapentin is fully discontinued:

• The initial 75 mg twice daily dose of pregabalin is appropriate when transitioning from gabapentin 1
• Increase to 150 mg twice daily (300 mg/day) within 1 week based on efficacy and tolerability 1
• The standard effective dose is 300 mg/day, which provides the optimal benefit-to-risk ratio for most neuropathic pain conditions 1
• Reserve the maximum dose of 600 mg/day only for patients with inadequate pain relief at 300 mg/day who tolerate the medication well 1

Pharmacokinetic Advantages of Pregabalin

The switch may offer practical benefits:

• Pregabalin has linear pharmacokinetics with 90% oral bioavailability, making dose adjustments more predictable than gabapentin's nonlinear absorption 1
• Pain relief typically occurs within 1.5–3.5 days with pregabalin, compared to 2+ months often required with gabapentin 1
• Twice-daily dosing (versus gabapentin's mandatory three-times-daily schedule) may improve adherence 1, 3

Common Pitfalls to Avoid

• Do not assume the patient will respond to pregabalin just because they are on gabapentin—patients may respond to one, both, or neither medication 1, 3
• Do not combine gabapentin and pregabalin beyond the brief transition period; there is no evidence supporting combination therapy, and the additive sedative burden creates unacceptable risk, especially in elderly patients 1
• Do not use standard doses in renal impairment—both medications require mandatory dose reduction based on creatinine clearance, as they are eliminated primarily by the kidneys 1

Special Population Considerations

For elderly patients or those with comorbidities:

• Consider lower starting doses (25–50 mg/day) and slower titration in elderly patients due to increased risk of dizziness, somnolence, confusion, and falls 1
• Calculate creatinine clearance before initiating pregabalin—dose reduction of approximately 50% is required for CLcr 30–60 mL/min, 75% for CLcr 15–30 mL/min, and 85–90% for CLcr <15 mL/min 1
• Use extreme caution in patients with edema or heart failure, as pregabalin can worsen fluid retention 1

Expected Side Effects

Prepare your patient for common adverse effects:

• Dizziness (23–46%) and somnolence (15–25%) are the most frequent dose-dependent side effects 1
• Peripheral edema (10%) and weight gain may occur, particularly problematic in elderly or obese patients 1
• Gradual titration over 1 week minimizes these side effects without requiring discontinuation 1